Riskpilot← Back to searchSign inGet full accessVetiqure AB
ABActiveOrg 5592672140Scheeletorget 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 20201-4 employees
Revenue 2024
SEK 5,4M
+141% vs 2023
EBITDA margin
31.2%
+179% vs 2023
Equity ratio
60.4%
Financial strength
Net profit 2024
SEK 1,8M
+184% vs 2023
| Revenue | SEK 5,4M | +141% |
| EBITDA | SEK 1,7M | +179% |
| Net profit | SEK 1,8M | +184% |
| Total assets | SEK 3,1M | +140% |
| Equity | SEK 1,9M | +1410% |
| Employees | — | — |
Legal name
Vetiqure AB
Org number
5592672140
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17 augusti 2020
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utveckling, produktion och marknadsföring av veterinärmedicinteknisk utrustning och därmed förenlig verksamhet.
Address
Scheeletorget 1
Email
aon@chemotech.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 1 701 | 3 393 | 2 254 | 5 424 |
| Staff expenses | — | — | — | — |
| EBITDA | 2 | 18 | −2 135 | 1 690 |
| Depreciation & amort. | −2 | −6 | −6 | −4 |
| EBIT | 0 | 12 | −2 141 | 1 686 |
| Net financials | — | −12 | 19 | 90 |
| Profit before tax | 0 | −1 | −2 123 | 1 776 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | 0 | −1 | −2 123 | 1 776 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 881 | 454 | 1 311 | 3 149 |
| Equity | 50 | 49 | 126 | 1 902 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 831 | 405 | 1 185 | 1 247 |
| Total debt | 831 | 405 | 1 185 | 1 247 |
EBITDA margin
31.2%
This company
15.8%
Market median
+97% vs market
20212024
Equity ratio
60.4%
This company
38.2%
Market median
+58% vs market
20212024
Return on equity
93.4%
This company
18.4%
Market median
+408% vs market
20212024
Net profit margin
32.7%
This company
8.1%
Market median
+304% vs market
20212024
Asset turnover
1.72×
This company
1.12×
Market median
+54% vs market
20212024
Debt / equity
0.66×
This company
0.62×
Market median
+6% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-08-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CF Chief Auditor | Chief Auditor | 2021 |
SM Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2022 – 2023 | |
| Chairman | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Scandinavian ChemoTech AB
Vetiqure AB Board members of Vetiqure AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Filip Mounir Åkesson | Chief Auditor | 0 companies |
| Stefan Mohan Frick | Chief Executive Officer | 0 companies |
| Robin Dev Sukhia | Chairman | 0 companies |
| Ann Charlotte Ohlsson | Board of Directors | 0 companies |
| Sven Anders Johnsson | Board of Directors | 0 companies |
| Lars Olof Hedbys | Chairman | 0 companies |